Patrick Plewman
Corporate Officer/Principal bei QUEST DIAGNOSTICS INCORPORATED
Vermögen: 2 Mio $ am 30.04.2024
Profil
Patrick Plewman is a professional who has worked in various firms.
He is a graduate of Harvard University with an MBA and also has an undergraduate degree from The University of North Carolina at Charlotte.
Currently, he is the Senior Vice President-Diagnostic Services at Quest Diagnostics, Inc. Previously, he worked as the President & Chief Executive Officer at VaxGen, Inc. in 2010, and at diaDexus, Inc. from 2000 to 2010.
He was also the President, Chief Executive Officer & Director at Diadexus, Inc. from 2010 to 2011.
Earlier in his career, he worked as the Director-Business Development at Smithkline Beecham Holdings Corp.
from 1989 to 1997.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 22.04.2024 | 16 062 ( 0,01% ) | 2 Mio $ | 30.04.2024 |
Aktive Positionen von Patrick Plewman
| Unternehmen | Position | Beginn |
|---|---|---|
| QUEST DIAGNOSTICS INCORPORATED | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Patrick Plewman
| Unternehmen | Position | Ende |
|---|---|---|
| DIADEXUS, INC. | Vorstandsvorsitzender | 01.07.2011 |
diaDexus, Inc. /Old/
 diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | Präsident | 01.11.2010 |
VaxGen, Inc.
 VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Präsident | 01.11.2010 |
Smithkline Beecham Holdings Corp.
 Smithkline Beecham Holdings Corp. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Smithkline Beecham Holdings Corp. produces and distributes pharmaceutical products and dental healthcare products. The company is based in Wilmington, DE. | Corporate Officer/Principal | 01.01.1997 |
Ausbildung von Patrick Plewman
| The University of North Carolina at Charlotte | Undergraduate Degree |
| Harvard University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| QUEST DIAGNOSTICS INCORPORATED | Health Services |
| Private Unternehmen | 4 |
|---|---|
diaDexus, Inc. /Old/
diaDexus, Inc. /Old/ Medical SpecialtiesHealth Technology diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field. | Health Technology |
Smithkline Beecham Holdings Corp.
Smithkline Beecham Holdings Corp. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Smithkline Beecham Holdings Corp. produces and distributes pharmaceutical products and dental healthcare products. The company is based in Wilmington, DE. | Health Technology |
VaxGen, Inc.
VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
Diadexus, Inc.
 Diadexus, Inc. BiotechnologyHealth Technology Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
